Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
4.0 CYPHER Sirolimus-Eluting Coronary Stent · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 4.0 CYPHER Sirolimus-Eluting Coronary Stent | DEVICE | 4.0 CYPHER Sirolimus-Eluting Coronary Stent |
Inclusion Criteria: 1. Male or non-pregnant female patients minimum 18 years of age 2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II) OR patients with documented silent ...
4.0 CYPHER Sirolimus-Eluting Coronary Stent is used for the treatment of coronary artery disease. It is a stent designed to be implanted in coronary artery lesions. The device is currently in Phase 3 clinical development and is being studied for its safety and effectiveness in patients with this condition.
4.0 CYPHER Sirolimus-Eluting Coronary Stent is developed by Cardinal Health, Inc., a company traded on the New York Stock Exchange under the ticker symbol CAH. The company is conducting clinical trials to evaluate the stent's use in patients with coronary artery disease.
4.0 CYPHER Sirolimus-Eluting Coronary Stent is in Phase 3 clinical development. It is an investigational device and has not been approved by regulatory authorities. A Phase 3 clinical trial has been completed to assess its use in treating coronary artery disease.
4.0 CYPHER Sirolimus-Eluting Coronary Stent has one completed clinical trial, identified as NCT00232752. This Phase 3 study, titled 'Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions,' enrolled 100 participants in the United States. The trial was not randomized or double-blinded and had no control group.
4.0 CYPHER Sirolimus-Eluting Coronary Stent is not FDA approved. It is an investigational device currently in Phase 3 clinical development. A completed clinical trial has evaluated its use in coronary artery disease, but regulatory approval has not been granted.